UroStream

Bladder-preserving treatment is an important therapeutic strategy for patients with muscle-invasive bladder cancer (MIBC), aiming to maintain bladder function while avoiding radical cystectomy. In recent years, this approach has become a major focus of clinical research, with multiple emerging strategies.

At the 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), one of the world’s most prestigious meetings in genitourinary oncology, multiple landmark studies were presented that are reshaping clinical practice. Among them, advances in urothelial carcinoma (UC) stood out prominently.

At the 2026 Genitourinary Cancers Symposium of the American Society of Clinical Oncology (ASCO GU 2026), held in San Francisco, leading experts from around the world gathered to present cutting-edge advances in urothelial carcinoma (UC). Key themes included antibody–drug conjugate (ADC) plus immunotherapy strategies for bladder preservation, clinical translation of liquid biopsy technologies, and deeper exploration of tumor molecular mechanisms.

The 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2026) has successfully concluded. As a global benchmark in genitourinary oncology, this year’s meeting delivered multiple landmark studies that provide strong evidence for optimizing and innovating prostate cancer management.

At the 2026 European Association of Urology Congress (EAU26), held in London, major advances in urologic oncology were presented. Among them, the work of Professor Xuesong Li’s team from Peking University First Hospital attracted considerable attention. The team not only contributed important achievements in upper urinary tract reconstruction but also presented a phase II clinical study of disitamab vedotin combined with radiotherapy for upper tract urothelial carcinoma (UTUC), offering a promising new treatment option.

At the 2026 European Association of Urology (EAU) Annual Congress held in London, leading experts from around the world gathered to discuss the latest advances and evolving clinical practices in genitourinary oncology. During the meeting, Oncology Frontier had the privilege of interviewing Professor Fred Saad from the Centre Hospitalier de l’Université de Montréal, who shared key insights into his team’s latest research, major breakthroughs in prostate cancer, and future therapeutic directions.

The 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2026) has successfully concluded, delivering multiple landmark advances that are reshaping clinical practice in urologic oncology.

The 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2026) brought together cutting-edge advances and landmark studies in genitourinary oncology from around the world.

Upper tract urothelial carcinoma (UTUC) is an aggressive malignancy of the urinary system, with high-risk subtypes associated with substantial risks of recurrence, metastasis, and poor prognosis. For decades, radical nephroureterectomy has been the standard treatment for high-risk UTUC. However, this approach inevitably leads to irreversible renal function impairment and may even result in renal failure, significantly compromising long-term quality of life.

At the 2026 ASCO Genitourinary Cancers Symposium (ASCO GU 2026), one of the world’s leading academic platforms in genitourinary oncology, Professor Jeremy Teoh (Yuan-Jin Zhang) and his team from The Chinese University of Hong Kong presented a series of landmark studies on en bloc resection of bladder tumor (ERBT). Backed by high-level evidence, these findings have positioned ERBT at the forefront of innovation in non–muscle-invasive bladder cancer (NMIBC), laying a solid clinical foundation for transforming treatment strategies.